Biologics Sports Medicine Ortho Regenerative Technologies Announces Enrollment of First Patient in its U.S. Phase l/ll Rotator Cuff Tear Repair Clinical Trial byChris StewartJuly 27, 2022
Biologics Sports Medicine Ortho Regenerative Technologies Initiates Patients Recruitment For Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial byChris StewartJune 13, 2022
Biologics Regulatory Sports Medicine Ortho Regenerative Technologies Receives Key U.S. Composition and Method Patent for Ortho-R Soft Tissue Repair Platform byChris StewartMay 4, 2022
Financial Ortho Regenerative Technologies Closes Oversubscribed Non-Brokered Private Placement for $3.2 Million byJosh SandbergApril 6, 2022
Biologics Extremities Sports Medicine Ortho Regenerative Technologies Announces Executive Leadership Changes byJosh SandbergMarch 15, 2022
Financial Ortho Regenerative Technologies Announces $3 Million Non-Brokered Private Placement of Units byChris StewartFebruary 11, 2022
Biologics Sports Medicine Ortho Regenerative Technologies Enters Into A Material Transfer Agreement With A Global Strategic Medical Company For Its Ortho-R Rotator Cuff Tear Repair Phase I/II U.S. Clinical Trial byChris StewartFebruary 7, 2022
Biologics Regulatory Top Stories Ortho Regenerative Technologies Announces U.S. IND Clinical Hold Lifted By The FDA & Clearance To Proceed With U.S. Clinical Trial byJosh SandbergDecember 13, 2021
Biologics Regulatory Sports Medicine Ortho Regenerative Technologies Announces Extension of FDA Clinical Hold of ORTHO-R Investigational New Drug Application byJosh SandbergAugust 20, 2021
Biologics Regulatory Ortho Regenerative Technologies Receives Clinical Hold Letter From the U.S. FDA byChris StewartJune 4, 2021
